Epizyme, Inc. (NASDAQ:EPZM) is set to announce second quarter earning results on Tuesday 4th August 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, EPZM to report 2Q20 loss of $ 0.61 per share.
For the full year, analysts anticipate top line of $ 29.95 million, while looking forward to loss of $ 2.39 per share bottom line.
Previous Quarter Performance
Epizyme, Inc. disclosed loss for the first quarter of $ 0.51 per share, from the revenue of $ 1.35 million. The quarterly revenues contracted 82.89 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.74 per share from $ 3.68 million in revenue. The bottom line results beat street analysts by $ 0.23 or 31.08 percent, at the same time, top line results fell short of analysts by $ 2.33 million or 63.32 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Epizyme, Inc.
Stock Performance
According to the previous trading day, closing price of EPZM was $ 14.37, representing a 47.54 % increase from the 52 week low of $ 9.74 and a 48.35 % decrease over the 52 week high of $ 27.82.
The company has a market capital of $ 1.45 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”EPZM” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 19th June 2020, maintained by Morgan Stanley at Overweight rating, with $ 31.00 target price.
Conference Call
Epizyme, Inc. will be hosting a conference call at 8:30 AM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.epizyme.com
Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The companys lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer.
